secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001213900-26-024352
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital
--------------------------------------------------------------------------------

- Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
- About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.
- SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.
- Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.
- Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/0001213900-26-024352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/ea0280257-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer